Streetbeat News

Analyst Ratings

TEAM

Truist Securities analyst Joel Fishbein maintains a 'Hold' rating on Atlassian (NASDAQ:TEAM) and lowers the price target from $200 to $180.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:42 pm

ITRI

Piper Sandler analyst Kashy Harrison maintains a Neutral rating on Itron (NASDAQ:ITRI) and raises the price target from $71 to $72.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:41 pm

IAS

Piper Sandler analyst Matt Farrell has maintained an Overweight rating on Integral Ad Science (NASDAQ:IAS) but lowered the price target from $23 to $20.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:40 pm

FOXF

Truist Securities analyst Michael Swartz has maintained a 'Buy' rating on Fox Factory Hldg (NASDAQ:FOXF), but lowered the price target from $120 to $90.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:39 pm

LNC

Piper Sandler analyst John Barnidge maintains a Neutral rating on Lincoln National (NYSE:LNC) and has lowered the price target from $27 to $25.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:37 pm

THG

Piper Sandler analyst Paul Newsome maintains an Overweight rating on Hanover Insurance Gr (NYSE:THG) and raises the price target from $138 to $143.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:34 pm

PODD

Piper Sandler analyst Matt O'Brien has maintained an Overweight rating on Insulet (NASDAQ:PODD), but lowered the price target from $325 to $250.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:32 pm

ALGS

Aligos Therapeutics, Inc. (NASDAQ:ALGS) will host a virtual KOL event to review the Late Breaking results and next steps for ALG-000184, its Phase 1 CAM-E drug candidate for chronic Hepatitis B (CHB). The event will feature Mark Sulkowski, MD, Professor of Medicine at the Johns Hopkins University School of Medicine, and will take place on November 16, 2023. The Phase 1 data are being featured in a late breaking poster session at the Liver Meeting® of the American Association of Liver Disease on November 13, 2023.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:32 pm

ELTX

Elicio Therapeutics (NASDAQ:ELTX) has presented updated preliminary data from its ongoing Phase 1 study of ELI-002, a therapeutic cancer vaccine, and new preclinical data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer Annual Meeting. The data shows promising results in patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers. The strength of the induced T cell response correlated with a significantly reduced risk of relapse and death. ELI-007 and ELI-008 also demonstrated strong induction of tumor-antigen-specific T cell responses in mice.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:31 pm

EXPE

Piper Sandler analyst Thomas Champion maintains an Overweight rating on Expedia Group (NASDAQ:EXPE) and raises the price target from $119 to $135.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:30 pm